Position:
Assistant Professor
Medical Oncologist
Division:
Medical Oncology
Vision Statement:

Daniel Renouf is a medical oncologist at the British Columbia Cancer Agency, Vancouver Centre, and an Assistant Professor at the University of British Columbia, Department of Medicine. He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and British Columbia Cancer Agency. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University. Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer. He is the leader of the BC Cancer Agency Phase I program, the Co-Director of Pancreas Centre BC and is the Co-chair of the NCIC pancreatic cancer disease group..

Research Interests:

Developmental Therapeutics, Pancreatic Cancer, Clinical Trials, Colorectal Cancer, Cancer Genomics, Cancer Biomarkers

Research Sumary:

Daniel’s research is focused on developing new treatments with emphasis on pancreatic cancer, and discovering markers to individualize cancer therapy.

Education:
Harvard School of Public Health, Boston, MA, 2011, MPH
University of Alberta, Edmonton, AB, 2004, MD, Special Training in Research
University of Alberta, Edmonton, AB, 2000, BSc Biological Sciences-Molecular Genetics (Honours), First Class
University of British Columbia, 2007, Internal Medicine Residency
University of British Columbia, 2009, Medical Oncology Residency
University of Toronto/Princess Margaret Hospital, 2011, Clinical Research Fellowship in New Drug Development
University of British Columbia, 2011, Clinician Investigator Fellowship Program
Affiliations
Pancreas Centre BC, Co-director
Recent Publications:

Link to PubMed

Awards & Recognition:
  • NCIC Clinical Trials Group Elizabeth Eisenhauer Early Drug Development Young Investigator Award (2014)
  • American Society of Clinical Oncology Merit Award (2011)
  • The Canadian Association of Medical Oncology Abstract Contest 2nd Prize (2010)
  • Novartis Oncology Young Canadian Investigators Award (2009)
  • The Canadian Association of Medical Oncology Abstract Contest 1st Prize (2009)
  • Canadian Western Oncology Conference Poster competition, 2nd prize (2009)
  • GB John Mancini prize for research achievement during residency (2008)
  • The Canadian Association of Medical Oncology Abstract Contest 1st Prize (2008)
  • The Royal College of Physicians and Surgeons of Canada, Chief Resident Conference Abstract Contest 3rd Prize (2008)
  • ASCO Amgen Canadian Fellows Alliance Program Scholarship (2008)
  • Canadian Western Oncology Conference Best Poster (2008)
  • The Canadian Association of Medical Oncology Abstract Contest 2nd Prize (2007)
  • Best Poster in Translational Research the British Columbia Cancer Agency Conference (2007)

2015-2019: Canadian Cancer Society Research Institute Impact Grant

New therapeutic strategy targeting tumour hypoxia and carbonic anhydrase IX for the treatment of pancreatic cancer (D. Renouf Co-PI)

2014-2019: NCI Experimental Therapeutics- Clinical Trials Network with Phase I Emphasis (UM1)

Princess Margaret Phase I Consortium (D. Renouf Co-PI)

2014-2016: National Pancreatic Cancer Canada Foundation

The effects of neoadjuvant metformin on tumour cell proliferation and tumour progression in pancreatic ductal adenocarcinoma (D. Renouf PI)

2014-2016: National Pancreatic Cancer Canada Foundation

Early Detection of pancreatic cancer ductal adenocarcinoma (D. Renouf Co-PI)

2014-2016: Bayer, Investigator Initiated Clinical Trial

A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib with Refractory Metastatic Colorectal Carcinoma (mCRC) (D. Renouf Co-PI)

2013-2014: British Columbia Cancer Agency Translational Research Initiative Evaluation of tumor hypoxia and therapeutic targeting of carbonic anhydrase IX/XII in pancreatic cancer (D. Renouf Co-PI)

2011-2013: Ontario Institute of Cancer Research Pharmacogenetic Study of Gemcitabine in Pancreatic Cancer: Analysis of Clinical and Observational Trials (D. Renouf Co-PI).

2009-2011: Oncology Drug Development Fellowship Funding provided by the Royal College of Physicians and Surgeons of Canada, Clinical Investigator Program

Dr. Renouf’s teaching interests include medical education in oncology, clinical trial design, epidemiology, and public health.